Literature DB >> 765779

Prostaglandins and inflammation in the eye.

E L Nelson.   

Abstract

Traumatic injury of the eye promotes the release of prostaglandins E2 and F2alpha from the iris and other tissues. These induce vasodilation, increased capillary permeability and an increase in protein content of the aqueous. They are leukotactic. With an influx of leukocytes PGE1 appears in the aqueous having been synthesized by these cells. Infectious agents also attract leukocytes and sensitized lymphocytes characterize inflammation of both allergic and infectious origin. The cascade of molecular and cellular events seen in ocular inflammation of various origin seem ultimately to result in a reaction largely mediated by prostaglandins. Effective therapy should be directed at preventing their synthesis (synthetase inhibitors), interferring with their action once synthesized (receptor blockers), and inhibiting the migration of leukocytes into the eye.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 765779

Source DB:  PubMed          Journal:  Mod Probl Ophthalmol        ISSN: 0077-0078


  4 in total

1.  Detection of Lipid Mediators of Inflammation in the Human Tear Film.

Authors:  Shyam Panthi; Jianzhong Chen; Landon Wilson; Jason J Nichols
Journal:  Eye Contact Lens       Date:  2019-05       Impact factor: 2.018

Review 2.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

Review 3.  The promise of stem cell-based therapeutics in ophthalmology.

Authors:  Israel Aharony; Shalom Michowiz; Nitza Goldenberg-Cohen
Journal:  Neural Regen Res       Date:  2017-02       Impact factor: 5.135

4.  Alternative Drug Delivery for Patients Undergoing Cataract Surgery as Demonstrated in a Canine Model.

Authors:  L David Waterbury
Journal:  J Ocul Pharmacol Ther       Date:  2017-12-11       Impact factor: 2.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.